...symptoms in breast and prostate cancer patients treated with hormone deprivation. Ogeda was known as Euroscreen S.A....

...symptoms in breast and prostate cancer patients treated with hormone deprivation. Ogeda was known as Euroscreen S.A....

...Ogeda S.A. , Brussels, Belgium Business: Genitourinary, Endocrine/Metabolic, Neurology Date announced: 2016-10-19 Note: Ogeda (formerly Euroscreen S.A....

...a double-blind, placebo-controlled, Belgian Phase IIa trial evaluating 90 mg oral ESN364 for 12 weeks. Euroscreen S.A....

...as did existing investors Vesalius Biocapital II Partners; SRIW; and BNP Paribas Fortis Private Equity. Euroscreen...

...commercialization. Euroscreen will receive an upfront payment and research funding over the next three years. Euroscreen...
...will have all rights to IP developed under the deal. Further terms were not disclosed. Euroscreen S.A....

...to isolate compounds that modulate biological activity of P2Y11 receptor patented; available for licensing from Euroscreen S.A....

...Euroscreen said the European Patent Office rejected an opposition filed by Progenics to Euroscreen's European Patent...
...140 , a mAb against CCR5 that is in Phase II testing to treat HIV. Euroscreen's...
...CCR5 sequences, vectors, cell lines and screening methods to identify compounds that modulate CCR5 activity. Euroscreen S.A....

...for any indication. Euroscreen is the licensing agent for the portfolio, which includes patents from Euroscreen...
..."the primary application of interest to companies at this time." Financial terms were not disclosed. Euroscreen S.A....